Document is current
Any future updates will be listed below
-
Authors
Agius, Michael P.
Song, Chen
Liu, Qi
Iemura, Tomoki
Hevenor, Laura
Payne, N. Connor
Pistofidis, Romanos Sklavenitis
Pantano, Lorena
Zhao, Hongfang
Seo, Hyuk-Soo https://orcid.org/0000-0003-0646-2102
Heilpern-Mallory, Daniel https://orcid.org/0000-0003-4296-015X
Heaslip, Caleb
Sun, Zhen-Yu J.
Bashyal, Puspalata
Aranha, Michelle P. https://orcid.org/0000-0002-8230-5726
Lightbody, Elizabeth
Mazitschek, Ralph https://orcid.org/0000-0002-1105-689X
Dhe-Paganon, Sirano https://orcid.org/0000-0003-0824-5929
Mitsiades, Constantine S. https://orcid.org/0000-0003-2321-8005
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 17 April 2026
First Online: 28 May 2026
Competing interests
: R.M. and N.C.P. are inventors on patent applications related to the CoraFluor TR-FRET technology used in this work (US 2022/002254). R.S.P. is a consultant, equity holder and co-founder of Predicta Biosciences. C.S.M. has served on the Scientific Advisory Board of Adicet Bio and discloses consultant/honoraria from Ionis, Genentech, Nerviano, Secura Bio and Oncopeptides, and research funding from EMD Serono, Karyopharm, Sanofi, Nurix, BMS, H3 Biomedicine/Eisai, Springworks, Abcuro, Novartis and OPNA. I.M.G. has consulting or advisory roles with AbbVie, Adaptive, Amgen, Aptitude Health, Bristol Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, The Binding Site and Window Therapeutics; has received speaker fees from Vor Biopharma and Veeva Systems; is a co-founder, equity holder and consultant for PreDICTA Biosciences; and her spouse is the CMO and an equity holder of Disc Medicine. J.Q. is a scientific co-founder and shareholder of Epiphanes, Inc. The other authors declare no competing interests.
